# US 2008/0188542 A1 · Novel indole polymorphs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188542 A1
- Document ID: US20080188542A1
- Status: Published application
- Kind: A1
- Application number: 12/026,235
- Filed: 2008-02-05
- Published: 2008-08-07
- Earliest claimed: 2007-02-05
- Assignees: Wyeth
- Inventors: Abdolsamad TADAYON; Hsueh-Ling Wu; Mannching Sherry Ku; David Zenan Li
- Web page: https://patentgrep.com/patent/US20080188542A1

## CPC

- C07D 209/22: with an aralkyl radical attached to the ring nitrogen atom
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel polymorphs, pharmaceutical compositions containing novel polymorphs, methods of using novel polymorphs and methods of preparing novel polymorphs of [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)-1H-indol-3-yl](oxo)acetic acid are described herein.

## Claims

### Claim 1

A polymorph (Form A) of [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)1H-indol-3-yl](oxo)acetic acid having a powder X-ray diffraction pattern comprising characteristic peaks, in terms of 2θ, at about 6.5° and 10.9°.

### Claim 2 (depends on 1)

The polymorph of claim 1 having a powder X-ray diffraction pattern further comprising characteristic peaks, in terms of 2θ, at about 18.6° and 24.2°.

### Claim 3 (depends on 1)

The polymorph of claim 1 having a powder X-ray diffraction pattern further comprising characteristic peaks, in terms of 2θ, at about 16.2° and 17.4°.

### Claim 4 (depends on 1)

The polymorph of claim 1 having a powder X-ray diffraction pattern further comprising characteristic peaks, in terms of 2θ, at about 15.2° and 25.8°.

### Claim 5 (depends on 1)

The polymorph of claim 1 wherein said powder X-ray diffraction pattern comprises at least 5 additional characteristic peaks, in terms of 2θ, selected from 13.7°, 15.2°, 16.2°, 17.4°, 18.6°, 19.8°, 20.4°, 21.0°, 22.0°, 24.2°, and 25.8°.

### Claim 6 (depends on 1)

The polymorph of claim 1 having a powder X-ray diffraction pattern further comprising characteristic peaks, in terms of 2θ, at about 9.9°, 11.5°, 13.7°, 14.2°, 14.5°, 15.2°, 16.2°, 17.4°, 18.6°, 19.8°, 20.1°, 20.4°, 21.7°, 22.0°, 24.2°, 24.9°, 25.8°, 26.1°, and 27.5°.

### Claim 7 (depends on 1)

The polymorph of claim 1 having an X-ray powder diffraction pattern substantially as shown in FIG. 1.

### Claim 8

A polymorph (Form A) of [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)1H-indol-3-yl](oxo)acetic acid having a differential scanning calorimetry trace showing a melting peak at about 138° C.; having onset about 134° C.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising a polymorph of claim 1, wherein at least 3% by weight of total [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)-1H-indol-3-yl](oxo)acetic acid in said composition is said polymorph.

### Claim 10 (depends on 9)

The composition of claim 9, wherein at least 50% by weight of total [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)1H-indol-3-yl](oxo)acetic acid in said composition is said polymorph.

### Claim 11 (depends on 9)

The composition of claim 9, wherein at least 90% by weight of total [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)1H-indol-3-yl](oxo)acetic acid in said composition is said polymorph.

### Claim 12 (depends on 1)

A method for treatment of:
(a) thrombosis or fibrinolytic impairment;
(b) myocardial ischemia;
(c) Alzheimer's disease;
(d) reducing amyloid beta levels;
(e) improving cognition;
(f) treating pre-senile or senile dementia; or
(g) treating amyotrophic lateral sclerosis;
in a mammal comprising the administration of an effective amount of compound according to claim 1 to a mammal in need thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the said thrombosis or fibrinolytic impairment is associated with formation of atherosclerotic plaques, venous or arterial thrombosis, myocardial ischemia, atrial fibrillation, deep vein thrombosis, coagulation syndromes, pulmonary fibrosis, cerebral thrombosis, thromboembolic complications of surgery or peripheral arterial occlusion.

### Claim 14 (depends on 12)

The method of claim 12, wherein amyloid beta levels are reduced in the brain.

### Claim 15 (depends on 12)

The method according to claim 12, wherein said mammal is a human.

### Claim 16 (depends on 1)

A method of preparing a polymorph of claim 1 comprising re-crystallization of [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)1H-indol-3-yl](oxo)acetic acid in one or more aromatic hydrocarbons, one or more polar non-protic solvents, or one or more dialkylethers, or combinations thereof.

### Claim 17 (depends on 16)

The method of claim 16 wherein said aromatic hydrocarbon comprises toluene; and said dialkylethers comprises of t-butyl methyl ether; and said polar non-protic solvents comprises acetonitrile.

### Claim 18 (depends on 1)

A method of preparing a polymorph of claim 1 comprising: treatment of [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)1H-indol-3-yl](oxo)acetic acid a) by heating in acetonitrile, cooling to from about 15° C. to about 30° C., treating with water and collecting the polymorph of claim 1; or b) by heating in toluene, addition of a non-aromatic hydrocarbon and collecting the polymorph of claim 1; or c) by heating in t-butyl methyl ether at a temperature sufficient for dissolution, addition of a non-aromatic hydrocarbon, seeding with polymorph of claim 1, and collecting the polymorph of claim 1.

### Claim 19 (depends on 18)

The method of claim 18 c) wherein additional non-aromatic hydrocarbon is added after seeding followed by cooling of the solution to a temperature between about 15° C. to about 30° C.

### Claim 20

A polymorph (Form B) of [1 -(4-tert-Butylbenzyl)-5-(3-methylphenyl)1H-indol-3-yl](oxo)acetic acid having a powder X-ray diffraction pattern comprising characteristic peaks, in terms of 2θ, at about 5.2° and 25.6°.

### Claim 21 (depends on 20)

The polymorph of claim 20 having a powder X-ray diffraction pattern further comprising characteristic peaks, in terms of 2θ, at about 15.5° and 16.1°.

### Claim 22 (depends on 20)

The polymorph of claim 20 having a powder X-ray diffraction pattern further comprising characteristic peaks, in terms of 2θ, at about 10.8 and 15.2°.

### Claim 23 (depends on 20)

The polymorph of claim 20 having a powder X-ray diffraction pattern further comprising characteristic peaks, in terms of 2θ, at about 23.0°, 23.6°, 24.3° and 26.6°.

### Claim 24 (depends on 20)

The polymorph of claim 20 wherein said powder X-ray diffraction pattern comprises at least 5 additional characteristic peaks, in terms of 2θ, selected from 10.8°, 15.2°, 15.5°, 16.1°, 23.0°, 23.6°, 24.3° and 26.6°.

### Claim 25 (depends on 20)

The polymorph of claim 20 having a powder X-ray diffraction pattern further comprising characteristic peaks, in terms of 2θ, at about 10.3°, 10.8°, 11.1°, 15.2°, 15.5°, 16.1°, 16.4°, 16.6°, 17.0°, 17.4°, 18.7°, 19.5°, 19.7°, 21.0°, 21.6°, 22.3°, 23.0°, 23.6°, 24.3°, 24.6°, 26.6°, 28.4°, 28.7°, 29.5°, 30.4°, 30.7°, 31.4°, 31.7° and 35.9°.

### Claim 26 (depends on 20)

The polymorph of claim 20 having an X-ray powder diffraction pattern substantially as shown in FIG. 6.

### Claim 27

A polymorph (Form B) of [1 -(4-tert-Butylbenzyl)-5-(3-methylphenyl)1H-indol-3-yl](oxo)acetic acid having a differential scanning calorimetry trace showing a melting peak at about 131° C.; having onset about 128° C.

### Claim 28 (depends on 20)

A pharmaceutical composition comprising a polymorph (Form B) of claim 20, wherein at least 3% by weight of total [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)-1H-indol-3-yl](oxo)acetic acid in said composition is said polymorph.

### Claim 29 (depends on 28)

The composition of claim 28 wherein at least 50% by weight of total [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)1H-indol-3-yl](oxo)acetic acid in said composition is said polymorph.

### Claim 30 (depends on 28)

The composition of claim 28 wherein at least 90% by weight of total [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)1H-indol-3-yl](oxo)acetic acid in said composition is said polymorph.

### Claim 31 (depends on 20)

A method for treatment of:
(a) thrombosis or fibrinolytic impairment;
(b) myocardial ischemia;
(c) Alzheimer's disease;
(d) reducing amyloid beta levels;
(e) improving cognition;
(f) treating pre-senile or senile dementia; or
(g) treating amyotrophic lateral sclerosis;
in a mammal comprising the administration of an effective amount of compound according to claim 20 to a mammal in need thereof.

### Claim 32 (depends on 31)

The method of claim 31, wherein the said thrombosis or fibrinolytic impairment is associated with formation of atherosclerotic plaques, venous or arterial thrombosis, myocardial ischemia, atrial fibrillation, deep vein thrombosis, coagulation syndromes, pulmonary fibrosis, cerebral thrombosis, thromboembolic complications of surgery or peripheral arterial occlusion.

### Claim 33 (depends on 31)

The method of claim 31, wherein amyloid beta levels are reduced in the brain.

### Claim 34 (depends on 31)

The method according to claim 31 wherein said mammal is a human.

### Claim 35 (depends on 20)

A method of preparing a polymorph of claim 20 comprising dissolution of [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)1H-indol-3-yl](oxo)acetic acid in one or more aromatic hydrocarbons followed by evaporation of solvent.

### Claim 36 (depends on 35)

The method of claim 35 wherein the aromatic hydrocarbon comprises toluene.

### Claim 37

A polymorph (Form C) of [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)1H-indol-3-yl](oxo)acetic acid having a powder X-ray diffraction pattern comprising characteristic peaks, in terms of 2θ, at about 5.4° and 6.8°.

### Claim 38 (depends on 37)

The polymorph of claim 37 having a powder X-ray diffraction pattern further comprising characteristic peaks, in terms of 2θ, at about 9.9° and 13.5°.

### Claim 39 (depends on 37)

The polymorph of claim 37 having a powder X-ray diffraction pattern further comprising characteristic peaks, in terms of 2θ, at about 6.0° and 16.2°.

### Claim 40 (depends on 37)

The polymorph of claim 37 having a powder X-ray diffraction pattern further comprising characteristic peaks, in terms of 2θ, at about 13.2°, 17.3°, 19.9° and 20.6°.

### Claim 41 (depends on 37)

The polymorph of claim 37 wherein said powder X-ray diffraction pattern comprises at least 5 additional characteristic peaks, in terms of 2θ, selected from 6.0°, 9.9°, 13.2°, 13.5°, 16.2°, 17.3°, 19.9° and 20.6°.

### Claim 42 (depends on 37)

The polymorph of claim 37 having a powder X-ray diffraction pattern further comprising characteristic peaks, in terms of 2θ, at about 6.0°, 9.9°, 10.9°, 13.2°, 13.5°, 16.2°, 17.0°, 17.3°, 19.5°, 19.9°, 20.6°, 21.2°, 22.120 , 23.0° and 24.5°.

### Claim 43 (depends on 37)

The polymorph of claim 37 having an X-ray powder diffraction pattern substantially as shown in FIG. 8.

### Claim 44

A polymorph (Form C) of [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)1H-indol-3-yl](oxo)acetic acid having a differential scanning calorimetry trace showing a melting peak at about 82° C.; having onset about 74° C.

### Claim 45 (depends on 37)

A pharmaceutical composition comprising a polymorph (Form C) of claim 37, wherein at least 3% by weight of total [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)-1H-indol-3-yl](oxo)acetic acid in said composition is said polymorph.

### Claim 46 (depends on 45)

The composition of claim 45 wherein at least 50% by weight of total [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)1H-indol-3-yl](oxo)acetic acid in said composition is said polymorph.

### Claim 47 (depends on 45)

The composition of claim 45 wherein at least 90% by weight of total [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)1H-indol-3-yl](oxo)acetic acid in said composition is said polymorph.

### Claim 48 (depends on 37)

A method for treatment of:
(a) thrombosis or fibrinolytic impairment;
(b) myocardial ischemia;
(c) Alzheimer's disease;
(d) reducing amyloid beta levels;
(e) improving cognition;
(f) treating pre-senile or senile dementia; or
(g) treating amyotrophic lateral sclerosis;
in a mammal comprising the administration of an effective amount of compound according to claim 37 to a mammal in need thereof.

### Claim 49 (depends on 48)

The method of claim 48, wherein the said thrombosis or fibrinolytic impairment is associated with formation of atherosclerotic plaques, venous or arterial thrombosis, myocardial ischemia, atrial fibrillation, deep vein thrombosis, coagulation syndromes, pulmonary fibrosis, cerebral thrombosis, thromboembolic complications of surgery or peripheral arterial occlusion.

### Claim 50 (depends on 48)

The method of claim 48, wherein amyloid beta levels are reduced in the brain.

### Claim 51 (depends on 48)

The method according to claim 48, wherein said mammal is a human.

### Claim 52 (depends on 37)

A method of preparing a polymorph of claim 37 comprising dissolution of [1-(4-tert-Butylbenzyl)-5-(3-methylphenyl)1H-indol-3-yl](oxo)acetic acid in a solution comprising an alcohol followed by crystallization and collection of the polymorph.

### Claim 53 (depends on 52)

The method of claim 52 wherein the solution comprising alcohol is heated to effect dissolution and cooled to effect crystallization.

### Claim 54 (depends on 52)

The method according to claim 52 wherein the solution comprising alcohol is treated with a non-aromatic hydrocarbon counter solvent prior to collection of the polymorph.

### Claim 55 (depends on 52)

The method according to claim 52 wherein the alcohol comprises ethanol; and the non-aromatic hydrocarbon counter solvent comprises heptane.
